ACTIV-4 ACUTE: COVID-19 Acute Inpatient Antithrombotic Study (Launched and Enrolling)

ACTIV-4 ACUTE: COVID-19 Acute Inpatient Antithrombotic Study (Launched and Enrolling)

ACTIV-4 ACUTE is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic strategies for prevention of adverse outcomes in patients hospitalized for COVID-19.

We invite you to join as a site for a clinical trial that aims to identify the most appropriate strategy to prevent adverse outcomes in the COVID-19 inpatients. For more information or to join, contact us at: ACTIV4ACUTE@nyulangone.org

For more information, please see the recent NIH Press Release; titled NIH ACTIV initiative launches adaptive clincal trials of blood-clotting treatments for COVID-19 (Link)

Date: 
Wednesday, October 7, 2020 - 14:00